Head-to-head evidence

BCMA CAR-NK (Hrain) vs Trovocabtagene autoleucel (C-CAR088)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

💬 Discuss in AI Terminal →

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Hrain)

Developed by Hrain Biotechnology Co., Ltd.

Phase 1/2 in Multiple Myelomacell therapy (allogeneic BCMA-targeted CAR-NK)

Weak signal

NCT05008536 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 27 participants. Results have not been posted yet. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)

Unlock with Research ↗

Trovocabtagene autoleucel (C-CAR088)

Developed by AbelZeta Pharma, Inc.

Phase 1/2 in Multiple MyelomaCAR-T cell therapy

Weak signal

NCT03751293 · Phase 1 · status unknown

This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.

Unlock with Research ↗

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Hrain)'s landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape